AC
BLPH

Armistice Capital’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Armistice Capital’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-59,000
Closed -$427K – 94
2019
Q3 		$427K Sell
59,000
-131,667
-69% -$1.2M 0.03% 66
2019
Q2 		$1.71M Sell
190,667
-2,666
-1% -$25.6K 0.11% 57
2019
Q1 		$1.89M Buy
+193,333
New +$2.13M 0.1% 65
2017
Q1 		– Sell
-66,667
Closed -$520K – 62
2016
Q4 		$520K Buy
+66,667
New +$928K 0.12% 48

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Armistice Capital's BLPH Position: Q4 2019 in Review

Armistice Capital sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q4 2019, closing a stake of 59,000 shares — an estimated $427K sold.

Armistice Capital first reported a position in BLPH in Q4 2016 and held it in 4 quarters. The position peaked at $1.89M in Q1 2019. 19 funds tracked by Wall St. Rank hold BLPH as of Q4 2019.

  • Armistice Capital reported no remaining Bellerophon Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
  • Armistice Capital sold 59,000 Bellerophon Therapeutics, Inc. shares in Q4 2019, an estimated $427K.
  • Armistice Capital first reported a position in Bellerophon Therapeutics, Inc. in Q4 2016 and held it in 4 quarters.
  • Armistice Capital's Bellerophon Therapeutics, Inc. position peaked at $1.89M in Q1 2019.
  • 19 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q4 2019.

Based on Armistice Capital's 13F filing for Q4 2019, filed 14 Feb 2020.